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INTRODUCTION
Keratoconus is a progressive noninflammatory disorder, characterized by corneal ectasia and thinning due to changes in collagen structure and biomechanical stromal weakening. Progression of this degenerative process is manifested by increasing corneal distortion, irregular astigmatism, progressive myopia and central corneal scarring, resulting in visual acuity deterioration.
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Mild cases may require spectacles or rigid permeable contact lenses, and in recent years also wavefront-corrected spectacles and soft contact lenses. 5 Mild to moderate keratoconus with unsatisfactory best-corrected visual acuity (BCVA) or contact lens intolerance may necessitate surgical intervention such as intracorneal ring segments implantation; however long-term follow-up demonstrates that the resulting refractive improvement is only temporary, and a significant progression of keratometry values in operated eyes has been reported. 6, 7 In cases of further progression of the ectasia and failure of the above mentioned tools, corneal transplantation is the treatment of choice in up to 20% of patients. 8, 9 A decade ago, Wollensak and associated have introduced a novel minimally invasive technique using riboflavin\UVA corneal collagen cross-linking (CXL), which has been shown to enhance corneal biomechanical stiffening, stabilize and even arrest progression of keratoconus in adult eyes, with no permanent deleterious effects, thus rendering corneal transplantation unnecessary in some patients. [10] [11] [12] [13] [14] [15] [16] [17] [18] It seems that keratoconus has a tendency to progress faster in children than in adults, and therefore the consequence of unsatisfactory visual acuity or contact lens intolerance may be encountered sooner. Vinciguerra and associates have recently reported their results of a 2 years follow-up after corneal CXL in patients younger than 18 years with documented progressive keratoconus. 19 According to their prospective study, CXL improved uncorrected and best spectacle corrected visual acuity (BSCVA) in the study patients, an improvement that was found to be statistically significant. However, in our previous study on pediatric keratoconus, the results were less conclusive, and apart from achieving stability in most patients, no statistically significant improvement was noted in any parameter. 20 Therefore, in this study, we retrospectively analyzed visual acuity, refractive and topographic outcomes in a larger group of patients (31 eyes in comparison to 9 eyes in our previous study) younger than 18 years with a documented progressive keratoconus in three different and independent medical centers in Israel.
MATERIALS AND METHODS

Patients
Thirty-one eyes of 21 patients in which keratoconus progression was documented in the preceding 6 months were enrolled to this retrospective study at 3 ophthalmology departments in Israel: Assaf Harofeh Medical Center, Sheba Medical Center and 'Enaim' Medical Center, during 2009-2013.
Inclusion criteria included: age younger than 18 years at the time of the procedure, progressive keratoconus and corneal thickness of at least 400 µm. Progression was defined as 1 or more of the following changes over a period of 6 months: an increase of at least 1.00 diopter (D) in K max , an increase of at least 1.00 D in manifest cylinder, an increase of at least 0.50 D in manifest refraction spherical equivalent (SE), loss of BSCVA of more than 2 lines or a subjective decrease in visual acuity (VA).
Exclusion criteria included: corneal thickness less than 400 µm at the thinnest point, severe surface disease, a history of herpetic keratitis, a previous ocular surgery, concurrent corneal infection, presence of central or paracentral corneal opacities or a documented autoimmune disease.
Distance UCVA and BSCVA (in log MAR) as well as manifest refraction were assessed using the Snellen chart preoperatively and 1, 3, 6, 12 and 24 months postoperatively. The refraction was meticulously evaluated by the operating surgeon. Topography measurements were obtained preoperatively and 1, 3, 6, 12 and 24 months postoperatively using a rotating Scheimpflug camera (Pentacam, Oculus, Inc.) or the TMS 4 topographic modeling system (TOMEY, Japan). Recorded parameters were maximum, minimum and average K values (K max , K min and K ave respectively), corneal astigmatism (simulated K) and corneal thickness.
Surgical Technique
Each one of the procedures were performed by four surgeons (DZ, IB, IA and SL), using the 'Dresden protocol' as previously published. 9 The surgical procedure was performed under topical anesthesia preceded by standard prepping and draping. The central zone of an area 8 mm in diameter corneal epithelium was removed using a blunt metal spatula. Drops of riboflavin 0.1% combined with dextran 20% were instilled every 2 minutes for 30 minutes. After achieving a strong yellow flare in the anterior chamber, the cornea was exposed to UV-A when the patient is in recumbent position. The patient was instructed to focus on the central LED of the probe and the surgeon also confirmed centration in order to achieve maximal stability throughout the procedure. The UV-A (365-370 nm) light was introduced via UVA source located 5 cm from the eye (UVX produced by IROC) with a light intensity of 3mW/cm 2 . Riboflavin eye drops continued to be administered every 2 minutes during the UV-A treatment. At the conclusion of eth procedure a bandage contact lens was applied and maintained until the re-epithelialization was complete. The postoperative treatment included topical Oflox (ofloxacin 0.3%) drops for 3 days, and FML (fluorometholone 0.1%) for 3 weeks.
Statistical Analysis
Statistical analysis was performed with SPSS software using (version 16, SPSS Inc) and the data was analyzed using the 2-tailed t-test for each parameter. Data is expressed as mean differences between pre and post for each parameter.
RESULTS
Thirty-one consecutive eyes of 21 patients were identified. All patients had CXL and had a follow-up period of 3 to 48 months (average, 23 ± 13.6 months). Twenty-five eyes (80%) completed at least 12 months of follow-up. All patients were males, and the mean age was 14.7 ± 1.6 years (11-17 years). Neither intraoperative nor postoperative complications were encountered, with the exception of one case of corneal haze in that resolved completely with topical steroids treatment.
Graphs 1 and 2 contain data concerning uncorrected and best spectacle corrected visual acuity, respectively, expressed in logarithm of minimal angle of resolution units. There was a slight improvement in UCVA that was statistically significant (0.74 ± 0.3 preoperatively and 0.64 ± 0.33 postoperatively, p = 0.039) and a modest statistically insignificant improvement in BSCVA (0.29 ± 0.22 preoperatively and 0.26 ± 0.17 postoperatively, p = 0.22). Visual acuity was evaluated at each encounter, as was elaborated earlier, but the data shown on the graphs express visual acuity at baseline and at the final encounter. Most of the patients achieved a long-term stability or improvement in both UCVA (22 of 31 eyes, 71%) and BSCVA (24 of 31 eyes, 77%). There was a nonstatistically significant reduction in manifest cylinder, There was no statistically significant change in average K max (52.55D pre-and 52.71D postoperatively, Graph 3), in K min (45.7D pre-and 46.1D postoperatively) or in K ave (48.7D pre-and 49.7D postoperatively).
DISCUSSION
Our results showed that CXL stabilized visual acuity, refractive and topography parameters in a pediatric population with progressive keratoconus.
In the last decade, corneal CXL with riboflavin and UV-A has become an important tool aiming stabilize the cornea in patients with keratoconus. This minimally invasive technique has been shown in several studies to be a safe and effective mean, being able to halt the progression of keratoconus, and thus preserve visual function, and even reduce the need for keratoplasty in some patients. 10, [21] [22] [23] [24] CXL performed in patients with documented progression of keratoconus it showed long-lasting stability of at least 24 months, and in some cases even improved visual acuity and corneal topographic indices with. [25] [26] [27] Keratoconus is often more advanced in children than in adults, with faster disease progression. Early detection and close monitoring are therefore crucial in young patients. 28 Therefore, CXL may play an even more important role in this high-risk population. Only a few studies reported CXL in pediatric keratoconus. Soeters et al 29 published a larger prospective study on CXL in 40 eyes of 40 patients younger than 18 years and reported a statistically significant (p < 0.05) improvement in UCVA (0.79 ± 0.21 at baseline and 0.58 ± 0.18 two years after the procedure) and BSCVA (0.39 ± 0.10 at baseline and 0.20 ± 0.09 two years after the procedure). They also reported a decrease in the value of spherical equivalent by 1.57D at 24 months with a concomitant improvement in all keratometric parameters. Although our study found visual acuity stability (improvement or no worsening) in most patients, only a slight and insignificant improvement UCVA and BSCVA was observed, with no change in corneal indices. We believe that these differences in outcomes could be related to a difference in patient selection between our study and Vinciguerra's study: keratoconus progression in the latter study was defined as a change in either myopia or astigmatism of at least 3 diopters in the previous 3 months, or a mean central K reading change of at least 1.5D observed in 2 consecutive topographies during the preceding 3 months. 19 On the other hand, in our study progression was defined as an increase of at least 1.00 D in K max , an increase of at least 1.00D in manifest cylinder, an increase of at least 0.50D in manifest refraction spherical equivalent (SE), loss of BSCVA of more than 2 lines or a subjective decrease in VA. Thus, the progression rate in Vinciguerra's study was significantly higher than in ours, meaning that progression in the former study was a definite fact and keratoconus was indeed rapidly progressing, while in this study we enrolled patients with a relatively modest progression. If that is the case, it may be cautiously assumed, that corneal cross-linking should still remain as an option to halt progression in younge r patients, but perhaps progression criteria should be more meticulously determined. The limitations of our study include the retrospective method of retrieval of the data performed in 3 centers, however using the same methods.
CONCLUSION
Our data support the safely of CXL in pediatric patients, which is capable of stabilizing visual acuity, refraction and corneal indices. Further larger scale prospective studies are required to determine the optimal indication criteria for CXL in children with keratoconus and to better predict the improvement in visual parameters and not only stabilization and preservation of the given status.
